# The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

> **NCT03292861** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Cedars-Sinai Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Heart Transplantation

## Interventions

- **DRUG:** Thymoglobulin
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Tacrolimus
- **DRUG:** Sirolimus
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT03292861
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2018-09-13
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03292861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03292861, "The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03292861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*